ASM INTERNATIONAL N.V. ANNOUNCES VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
Almere, the Netherlands
May 17, 2021, 9 p.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) today announces the voting results of its Annual General Meeting of Shareholders held on May 17, 2021, at the ASM offices, the Netherlands.
The shareholders approved all resolutions as proposed to the Annual General Meeting of Shareholders.
The main approved resolutions include the following:
Mr. Paul Verhagen was appointed as a member of the Management Board and will succeed Mr. Peter van Bommel as Management Board member and as CFO. Mrs. Stefanie Kahle-Galonske was re-appointed as Supervisory Board member for a term of four years. Furthermore the financial statements for the year 2020 were adopted, and the shareholders discharged the members of the Management Board and Supervisory Board from liability in relation to the exercise of their duties in the financial year 2020. The shareholders also voted in favor of a regular dividend payment of €2.00 per common share, and the withdrawal of 500,000 common shares.
About ASM International
ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Investor and Media contact:
T: +31 88 100 8500
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt17.6.2021 10:25:55 CEST | Pressemelding
STOCKHOLM, SVERIGE 17 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics rapporterar positiva resultat från en pågående fas 1/2-studie av bolagets läkemedelskandidat eprenetapopt i kombination med venetoklax och azacitidin i patienter med TP53-muterad akut myeloisk leukemi, AML. Studieresultaten visar att behandlingen uppnår studiens förutbestämda primära effektmått med fullständig remission i 37% av de utvärderade fallen. Studieresultaten baseras på en analys av 30 evaluerbara patienter där fullständig remission (CR) uppmättes i 37% av fallen. Den sammanlagda remissionsfrekvensen i kombination med ofullständig remission (CRi), CR/Cri, var 53%. Enligt studiens tillämpade design (Simon 2-stage) uppnåddes därmed det förutbestämda primära effektmåttet avseende fullständig remission. I den fortsatta delen av fas 1/2-studien ingår elva patienter som erhåller kombinationsterapin och monitoreras avseende säkerhet och behandlingse
Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia17.6.2021 10:25:55 CEST | Press release
STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company’s candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients. The results are underpinned by an analysis performed on 30 evaluable patients, demonstrating complete remission in 37% of the cases. the composite response rate, i.e. CR combined with CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%. The pre-defined primary efficacy endpoint concerning complete remission was thus reached in accordance with the applied study design (Simon’s 2-stage). Eleven patients remain on the study treatment and is continuously monitored on safety and efficacy para
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.6.2021 10:10:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-06-17Loan192Coupon1.00 %ISIN-codeSE0010133207Maturity2023-03-15 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln1,600Volume bought, SEK mln800Number of bids2Number of accepted bids1Average yield-0.064 %Lowest accepted yield-0.064 %Highest yield-0.064 %% accepted at lowest yield 100.00 Auction date2021-06-17Loan1588Coupon1.50 %ISIN-codeSE0011063015Maturity2024-03-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln5,500Volume bought, SEK mln2,000Number of bids6Number of accepted bids2Average yield0.032 %Lowest accepted yield0.031 %Highest yield0.034 %% accepted at lowest yield 62.50 Auction date2021-06-17Loan151 Coupon1.00 %ISIN-codeSE0013486156Maturity2030-06-12 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln1,600Volume bought, SEK mln700Number of bids4Number of accepted bids3Average yield0.853 %Lowest accepted yield0.851 %Highest yield0.861 %% accepted at lowest yield 71.43 Auc
Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark17.6.2021 10:00:00 CEST | Press release
Press Release Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark Nokia to accelerate rollout following the availability of 3.5GHz spectrum; the enhanced services will offer premium 5G speeds to customers The move builds upon Nokia’s long-standing partnership with TTN as lead supplier of 5G RAN Radio 17 June 2021 Espoo, Finland – Nokia continues to build upon its ongoing business with leading Danish mobile operators, Telenor and Telia via their joint network (TTN) accelerating the delivery of 5G services nationwide following the availability of 3.5 GHz spectrum. Nokia is the exclusive supplier of 5G RAN and will support the modernization of the shared network ensuring TTN’s three million customers have the best connectivity experiences. The availability of spectrum in the 3.5GHz band will offer incredibly fast 5G speeds to customers. The modernization deal will focus initially on Denmark’s four largest cities before expanding to cover most Danish customers during 20
Share Buyback Transaction Details June 10 – June 16, 202117.6.2021 10:00:00 CEST | Press release
Share Buyback Transaction Details June 10– June 16,2021 June 17, 2021 - Wolters Kluwer today reports that it has repurchased 68,486of its own ordinary shares in the period from June 10, 2021, up to and including June 16, 2021, for €5.6million and at an average share price of €81.21. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 2,697,810191.971.13 For the period starting May 6, 2021, up to and including August 2, 2021, we have engaged a third party to execute €70 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are added to
Board of Directors Declares Share Buyback17.6.2021 08:33:39 CEST | Press release
17 June 2021 Board of Directors Declares Share Buyback On 16 June 2021, Acron’s Board of Directors resolved that the Company repurchase its outstanding shares as envisaged by clause 2, Article 72 of the Federal Law On Joint-Stock Companies. The number of shares sought shall not exceed 4,053,400, which is 10 per cent of the authorised capital. The repurchase price shall be RUB 6,050 per share. Therefore, the buyback amount shall not exceed RUB 24.5 billion. Shareholders may apply for repurchase from 8 July 2021 through 6 August 2021 inclusive. The repurchased shares shall be paid on or before 21 August 2021. If the total number of shares tendered by the Company’s shareholders exceeds 4,053,400, shares shall be repurchased from selling shareholders on a pro rata basis. A notification of the share buyback shall be posted on the Company’s website at https://www.acron.ru/en on or before 17 June 2021. Media contacts: Sergey Dorofeev Anastasia Gromova Tatiana Smirnova Public Relations Phone:
Eurocastle Announces 2021 AGM Results and PDMR Dealing Notification17.6.2021 08:00:00 CEST | Press release
Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Announces 2021 AGM Resultsand PDMR Dealing Notification Guernsey, 17 June 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces the results of its 2021 Annual General Meeting held yesterday, 16 June 2021. All ordinary and extraordinary business tabled before the meeting in accordance with the Notice of Annual General Meeting circulated to shareholders on 26 May 2021 was approved. A copy of this Notice is available on Eurocastle’s website at www.eurocastleinv.com under Periodic Reports and Shareholder Communications in the Investor Relations Section. In addition the Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following